A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs PRO 140 (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Registrational; Therapeutic Use
- Sponsors CytoDyn
- 11 Apr 2018 According to a CytoDyn Inc. media release, company will Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018
- 09 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.
- 09 Mar 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jul 2018.